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Abstract
Objectives To date, PROPELLER MRI, a breathing-motion-
insensitive technique, has not been assessed for cystic fibrosis
(CF) lung disease. We compared this technique to CT for
assessing CF lung disease in children and adults.
Methods Thirty-eight stable CF patients (median 21 years,
range 6-51 years, 22 female) underwent MRI and CT on the
same day. Study protocol included respiratory-triggered PRO-
PELLER MRI and volumetric CT end-inspiratory and -
expiratory acquisitions. Two observers scored the images
using the CF-MRI and CF-CTsystems. Scores were compared
with intra-class correlation coefficient (ICC) and Bland-
Altman plots. The sensitivity and specificity of MRI versus
CTwere calculated.
Results MRI sensitivity for detecting severe CF bronchiecta-
sis was 0.33 (CI 0.09-0.57), while specificity was 100 % (CI
0.88-1). ICCs for bronchiectasis and trapped air were as fol-
lows: MRI-bronchiectasis (0.79); CT-bronchiectasis (0.85);
MRI-trapped air (0.51); CT-trapped air (0.87). Bland-Altman
plots showed an MRI tendency to overestimate the severity of
bronchiectasis in mild CF disease and underestimate bronchi-
ectasis in severe disease.
Conclusions Motion correction in PROPELLER MRI does
not improve assessment of CF lung disease compared to CT.
However, the good inter- and intra-observer agreement and
the high specificity suggest that MRI might play a role in the
short-term follow-up of CF lung disease (i.e. pulmonary
exacerbations).
Key Points
• PROPELLER MRI does not match CT sensitivity to assess
CF lung disease.
• PROPELLER MRI has lower sensitivity than CT to detect
severe bronchiectasis.
• PROPELLER MRI has good to very good intra- and inter-
observer variability.
• PROPELLER MRI can be used for short-term follow-up
studies in CF.
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Introduction
Cystic fibrosis (CF) is the most common genetic disease, caus-
ing a reduced life expectancy in Caucasians [1]. Life expec-
tancy is reduced because of progressive lung disease,
characterised by several structural lung changes, most impor-
tantly bronchiectasis and trapped air [2, 3]. To guide therapy to
prevent or reduce bronchiectasis and trapped air, it is crucial to
monitor CF lung disease at regular intervals.
CF lung disease monitoring has changed in the last decade
[4, 5]. Nowadays, computed tomography (CT) is considered
the most sensitive method to monitor CF lung disease in early
and advanced stages [6] and is usually preferred over chest x-
rays. The main disadvantage of CT is that it exposes patients
to ionising radiation. Therefore, CT protocols for CF are usu-
ally low or ultra-low dose [7, 8]. Despite this relatively low
radiation dose, it restricts the use of chest CT, especially in
children, who are more sensitive to radiation exposure than
adults [9]. Furthermore, ionising radiation limits the frequency
with which chest CT can be repeated for short- and long-term
monitoring of CF lung disease [10]. Magnetic resonance im-
aging (MRI), as a radiation-free technique, has been intro-
duced as an alternative to CT [11, 12]. To date, MRI has been
directly compared to CT in only a few studies, using various
MRI sequences [13–15], but none of those included motion
correction free-breathing sequences, such as PROPELLER.
The PROPELLER sequence has been designed to be relative-
ly insensitive to respiratory movements, as it enables correc-
tion of in-plane motion, rotation and translation [16, 17].
Moreover, PROPELLER is applied and increasingly proposed
as a respiratory-triggered sequence in non-compliant patients,
such as patients not able to perform breath-hold manoeuvres
(i.e. CF children) [18]. Finally, to date PROPELLER has not
been compared to CT for CF. Therefore, our study aims to
assess whether the breathing motion correction of PROPEL-
LER MRI improves the diagnostic performance of MRI ver-
sus CT to assess CF lung disease in a group of stable CF
patients who had both examinations performed on the same
day.
Material and methods
Stable CF patients were consecutively recruited in two CF
centres by their treating clinicians. A CF patient was defined
as stable when no signs or symptoms of acute or recent pul-
monary exacerbations were present as defined in the exclusion
criteria. Inclusion and exclusion criteria were as follows:
Inclusion criteria: CF proven by a positive sweat test,
genotyping and clinical symptoms; willing and able to partic-
ipate in the study; scheduled for biennial routine chest-CT
requested by the attending physician; ability to comply with
instructions during MRI and CT examinations; informed
consent.
Exclusion criteria: minimum age of 6 years; chronic oxy-
gen therapy; present or recent (2 weeks) pulmonary exacerba-
tion defined as treatment with intravenous antibiotics (non-
stable); history of lung transplantation; participation in other
trials; contraindications for MRI; possible pregnancy.
On the same day, prior to MRI and CT, each patient
underwent a clinical examination and spirometry
(Masterscope, Jaeger-Care Fusion, Germany). Spirometry
was performed according to the BATS/ERS guidelines^ [19].
Approval for this multicentre prospective cohort study was
obtained by the institutional review boards of both participat-
ing centres.
MRI and CT protocol
The MRI protocol was performed in 1.5T scanners (Avanto,
Siemens, Enlargen Germany) as follows: 16-channels torso
superficial coil; PROPELLER (BLADE@Siemens) sequence
proton density (PD) weighted with respiratory triggering
(Navigator@Siemens) at end-expiration; (TR/TE/alpha/TA:
2000/27 ms/150°/18 s, Ø=5 mm) axial and coronal. Average
time per acquisition was 7 to 10 min. The complete MRI
protocol lasted on average 35 min (range 20-45 min).
The CT protocol was performed in 16- or 64-rows scanners
(Sensation, Siemens, Erlangen, Germany) as follows: volu-
metric end-inspiratory and end-expiratory optimised-dose
scans, 100 kV for children <35 kg and 120 kV for children
≥35 kg, mAs 15-40, scan range lung apices to bases, slice
collimation 1 mm, slice thickness (Ø) 1 mm, reconstruction
increment 0.8 mm and pitch 1. For comparison with MRI,
multiplanar reconstructions (axial, coronal) with a slice thick-
ness of 5 mm and kernels B31f, B60f and B70f were obtained.
BothMRI and CT protocols did not include the administration
of a contrast agent.
Image analysis – CTand MRI
All MRI and CT images were anonymised and scored in ran-
dom order by two independent radiologists (G.S. and P.C.),
who were experienced in scoring and had 2 and 4 years of
experience in thoracic CTandMR imaging, respectively. Both
radiologists were blinded to all clinical information.
To score CTs, we used the CF-CT scoring system (CF-CT)
[20]. The total CF-CT score is the sum of the following sub-
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scores: bronchiectasis, mucous plugging, peribronchial thick-
ening, parenchymal score and trapped air. Each of the five
sub-scores is rated according to presence and severity, in each
of the six lobes, with the lingula as a separate lobe. All scores
and sub-scores are expressed as a percentage of the maximum
possible score, ranging from 0 (no pathological findings) to
100 (maximum severity).
To score MRI images, we used a CF-MRI scoring system
that is equivalent to the CF-CT scoring system and has been
used in previous studies [13, 14]. To train both observers,MRI
images of 16 patients excluded from the final analysis because
of incomplete CT data sets (absence of end-expiratory scan)
were used. Consensus meetings were held during and at the
end of scoring all MRIs of the training set. To determine intra-
observer agreement, observer 1 (P. C.) scored all CT and MRI
images twice, separated by 2 months to avoid recall bias.
Statistical analysis
Inter- and intra-observer agreement
Intra-class correlation coefficients (ICCs) were used to evalu-
ate inter- and intra-observer agreement for both MRI and CT
scores. ICC values between 0.4 and 0.6, 0.6 and 0.8 or ≥ 0.8
are considered to indicate moderate, good and very good
agreement, respectively [21].
To assess pairwise inter- and intra-observer agreement be-
tween MRI and CT scores, Bland-Altman and identity plots
were created for: (1) MRIobs1 vs. MRIobs2; (2) CTobs1 vs.
CTobs2 and (3) MRIobs1 vs. MRIobs1 and CTobs1 vs. CTobs1.
To compare MRI scores with CT scores, we evaluated
MRImean obs 1+2 vs. CTmean obs 1+2. All statistical analyses were
performed using SPSS 16.0 (SPSS, Chicago, IL), and STATA
12.0 (STATA, College Station, TX).
Sensitivity, specificity, PPVand NPVof MRI versus CT
The CF-CT bronchiectasis sub-score was used as the main
indicator of CF lung disease severity in order to determine
the sensitivity, specificity, positive predictive values (PPVs)
and negative predictive values (NPVs) of MRI versus CT.
Bronchiectasis has been recognised as a well-validated
and clinically relevant outcome measure in CF [2]. Using
chest CT as the reference test, a cut-off value of 26 % or
higher, representing severe bronchiectasis, was defined as
a true-positive finding for the MRI-bronchiectasis sub-
score; 26 % represents the percentage of the maximum
possible score for bronchiectasis, which is 12 per each
lobe and 72 in total according to CF-CT. This cut-off of
26 % was based on the median value of bronchiectasis
severity observed in two cohort studies, with either mild
or severe CF lung disease [3, 22], using receiver-
operating characteristic analysis to determine different
cut-off values. Sensitivity, specificity, PPV and NPV
were calculated for each observer (obs1 and obs2), in
addition to the mean of the bronchiectasis scores of both
observers (mean obs1+2).
Table 1 Baseline patient characteristics
Demographic data Value
No. patients 38
Female sex 22 (56 %)
Age, years 21 (6-51)
Morphofunctional data Value
FEV1 % predicted 75 (51.1-109.9)
Total CF-CT 25.9 (1.4-49.1)
Total CF-MRI 20.5 (0-39.6)
CT-bronchiectasis 22.7 (1.4-45.9)
MRI-bronchiectasis 18 (0-35)
CT-trapped air 46.3 (0-67)
MRI-trapped air 37 (0-66)
FEV1% = Forced expiratory volume in 1 sec% predicted. CF-CT = cystic
fibrosis computed tomography total score, CF-MRI = cystic fibrosis mag-
netic resonance imaging total score, CT-bronchiectasis = computed to-
mography bronchiectasis sub-score, MRI-bronchiectasis = magnetic res-
onance imaging bronchiectasis sub-score, CT-trapped air = computed
tomography trapped air sub-score, MRI-trapped air = magnetic resonance
imaging trapped air sub-score. The maximum absolute scores for CF-CT/
CF-MRI, bronchiectasis and trapped air sub-scores are 243, 72 and 27
respectively. Data are presented as median percentage of the maximum
score and range
Table 2 Prevalence of total MRI, total CT, bronchiectasis MRI, bronchiectasis CT, trapped air MRI and trapped air CT scores expressed in quartiles
Quartiles CF-CT CT-bronchiectasis CT-trapped air CF-MRI MRI-bronchiectasis MRI-trapped air
First (25 %) 17 15 25.9 15.8 13 27.8
Third (75 %) 36 28.9 60 29 22.7 44
CF-CT = cystic fibrosis computed tomography total score, CF-MRI = cystic fibrosis magnetic resonance imaging total score, CT-bronchiectasis =
computed tomography bronchiectasis sub-score, MRI-bronchiectasis = magnetic resonance imaging bronchiectasis sub-score, CT-trapped air = com-
puted tomography trapped air sub-score, MRI-trapped air = magnetic resonance imaging trapped air sub-score. Data are presented as percentage of the
maximum score no. (%). For instance a CF-CTof 17 for the first quartile means that 25% of the patients had a total CF-CTscore ≤ 17% of the maximum
bronchiectasis score
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Descriptive statistics were used to characterise the patients
at the time of their MRI and CTs. All scoring data are numer-
ical with results expressed as median (range) and scores
expressed as percentage of the maximum possible score.
Results
In this study, we enrolled 54 patients. Sixteen were excluded
from the analysis because of missing the end-expiratory CT
scans. MRIs of these 16 patients were used for training the
observers. Hence, 38 patients with stable CF (median 21 years,
range 6-51 years, 22 female) were eligible for the comparison
of CTs and MRIs. Baseline characteristics are shown in
Table 1. Prevalence of bronchiectasis, trapped air, total
CF scores with MRI and CT represented as the first and
third quartiles are shown in Table 2.
Inter- and intra-observer agreement for MRI versus CT
Inter- and intra-observer agreement, expressed as ICCs, for
MRIobs1 vs. MRIobs2, CTobs1 vs. CTobs2, MRImean obs 1+2 vs.
CTmean obs 1+2, CTobs1 vs. CTobs1 and MRIobs1 vs. MRIobs1 are
summarised in Table 3. In summary, the inter- and intra-
observer agreement for MRI was good or very good, although
lower than for CT. The ICCs for CF-CT sub-scores were
higher compared to CF-MRI sub-scores, especially for
peribronchial thickening and trapped air. Trapped air measure-
ment by MRI did not match with CT as showed by the ICC
values: CT-trapped air (0.87); MRI-trapped air (0.51) and
MRI/CT-trapped air (0.46). Finally, the intra-observer agree-
ment for the observer 1, who repeated the score twice, was
overall very good, but lower for MRI than for CT. Bland-
Altman and identity plots showed that PROPELLER MRI,
for almost all sub-scores, tends to overestimate mild CF cases
and underestimate severe CF cases (Figs. 1 and 2).
Table 3 ICC values of inter- and intra-observer agreement between observers for all sub-scores, CF-MRI total score and CF-CT total score
CF lung alterations MRIobs1 vs. MRIobs2 CTobs1 vs. CTobs2 MRImean obs 1+2 vs. CTmean obs 1+2 MRIobs1 vs. MRIobs1 CTobs1 vs. CTobs1
Bronchiectasis 0.79 0.85 0.78 0.83 0.92
Air wall thickening 0.60 0.74 0.79 0.81 0.95
Mucus 0.79 0.91 0.76 0.90 0.94
Parenchyma 0.85 0.91 0.84 0.92 0.88
Trapped air 0.51 0.87 0.46 0.81 0.91
Total score 0.80 0.93 0.82 0.91 0.96
Note that trapped air assessment shows the lowest ICC values, indicating poor agreement ofMRI with CT. Moreover the bronchiectasis score agreement
tends to decrease between observers from CT vs. CT to MRI vs. MRI and MRI vs. CT comparison
Average bronchiectasis sub-score (MRImean-CTmean)
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Fig. 1 Bland-Altman plot of
MRImean obs 1+2 vs. CTmean obs 1+2.
All scoring data are numerical and
scores are expressed as
percentage of the maximal
possible score. Horizontal axis:
average bronchiectasis sub-score
[(MRImean + CTmean)/2]; vertical
axis = difference in the bronchi-
ectasis sub-score (MRImean -
CTmean). Red and green lines
represent mean and ±2 standard
deviations (SD) respectively
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Sensitivity, Specificity, PPV and NPV
Sensitivity of MRI to detect severe bronchiectasis was low.
Using the cut-off value of 26 %, MRI identified 6 (16 %) and
CT 14 (38 %) patients with severe bronchiectasis. This was
true for both observers (obs1=25 %; obs2=50 %) and also
when the mean of both observers was used for analysis (mean
obs1+2=33 %). Specificity for MRI to detect severe bronchi-
ectasis was very high: obs1=95 %; obs2=100 % and average
of obs1+2=100 %. Similarly the PPVof MRI was high, while
the NPV was low, using either observer scores or the average.
Sensitivity, specificity, PPVand NPV values for each observer
and as an average of both observers are shown in Table 4.
Discussion
In this prospective two-centre study, we compared a motion-
insensitiveMRI sequence, PROPELLER, to CT to assess lung
disease in a group of stable CF patients. This study showed
that PROPELLERMRI is not as good as CT to assess CF lung
disease. Moreover, our study confirmed low sensitivity of
MRI compared to CT to detect trapped air.
First, we showed that althoughMRI had good or very good
inter- and intra-observer agreement, this was lower than for
CT.Moreover, the inter-observer agreement forMRI was low-
er than for CT, indicating that it was more difficult for the
observers to scoreMRIs compared to scoring CTs. In previous
studies the inter-observer agreement between MRI and CT
scores ranged from moderate to very good, while intra-
observer agreement was not assessed [13, 14]. In our study,
the intra-observer agreement was very good, thus suggesting
that the technique is robust, although less sensitive than CT.
Second, we confirmed that trapped air could not be reliably
visualised with MRI, as previously demonstrated by Failo
et al. and more recently by Rajaram et al. [14, 15]. Trapped
air is an early change associated with small airways disease [3,
23]. Unfortunately ourMRI protocol was not sensitive enough
to differentiate trapped air from surrounding normal lung pa-
renchyma. However, we believe that innovative sequences
can be added to the MR examination that might be more
sensitive to detect trapped air, such as the recently developed
Fourier decomposition [24].
Third, in our study with PROPELLER, MRI tended to
overestimate mild CF lung disease and underestimate severe
CF lung disease compared to CT. CTappears to have superior
sensitivity especially for changes in the periphery of the lung,
where small abnormalities, such as bronchiolectasis and
Fig. 2 Identity plot MRI-
bronchiectasis versus CT-
bronchiectasis sub-scores (mean
score observer 1+oserver 2).
Green line identity line Y=1 *
X+0. Note that MRI tends to
overestimate mild CF cases and
underestimate severe CF cases
(red line)
Table 4 Differentiation of mild versus severe CF lung disease using
chest MRI
Parameter Value C.I (95 %)
Sensitivityobs1 0.25 (4/15) 0.11-0.49
Sensitivityobs2 0.50 (9/18) 0.24-0.76
Sensitivityobs1+2 0.33 (5/15) 0.09-0.57
Specificityobs1 0.95 (19/20) 0.86-1
Specificityobs2 1 (20/20) 0.90-1
Specificityobs1+2 1 (23/23) 0.88-1
PPVobs1 0.8 (3/4) 0.24-1
PPVobs2 1 (8/8) 0.8-1
PPVobs1+2 1 (6/6) 0.55-1
NPVobs1 0.64 (21/34) 0.46-0.81
NPVobs2 0.69 (20/30) 0.51-0.87
NPVobs1+2 0.63 (20/32) 0.45-0.80
PPV = positive predictive value; NPV = negative predictive value. Data
are presented as ratio, with absolute values in brackets
784 Eur Radiol (2016) 26:780–787
mucus plugs can be easily missed by MRI (Fig. 3). To
overcome this problem, it is important to further increase
the spatial resolution of our routine MRI protocol. This
is likely possible with new techniques, such as 3D T1
GRE sequences with radial acquisition in free breathing
or in breath-hold condition and highly accelerated parallel
imaging [25].
Finally, we found a low sensitivity and NPV for MRI to
detect severe bronchiectasis compared to CT. This finding
partially matches the study of Puderbach et al., where the
lowest level of concordance between MRI and CT was for
the severity of bronchiectasis [13]. Similarly, Failo et al. dem-
onstrated the lower spatial resolution of MRI relative to CT,
especially at the periphery of the lung [14]. Conversely, we
found a high specificity and PPV for MRI, which indicates
that in case a structural abnormality is observed on MRI it is
also visible on CT. Thus, such an abnormality on MRI can be
further followed by MRI, avoiding CT. The high specificity
with the very good intra- and inter-observer agreement of
PROPELLER might be highly advantageous for short-term
follow-up of CF patient with pulmonary exacerbation. The
use of PROPELLER could allow assessing the efficacy of
antibiotic therapy without exposing the patient to ionising
radiation. Moreover, PROPELLER might even be suitable
for really young patients who are not capable of breath-hold
acquisition or in those sick CF patients with reduced
compliance.
There are some limitations that might have reduced the
agreement between MRI and CT in our study. The main lim-
itation is that we evaluated a single sequence, whichmay have
influenced the sensitivity of MRI to detect CF lung disease.
We used a single sequence study design as in prior publica-
tions [13, 14] because wewanted to assess whether the motion
correction technique of PROPELLER would have resulted in
improved image quality in chest MRI by reducing the impact
of respiratory movements [26]. However, a potential limita-
tion of the use of PROPELLER is that this sequence can
produce streak artefacts related to the K-space reconstruction
[16, 17]. To reduce this artefact we increased the blade width
and k-space coverage [27]. However, despite this adaptation,
streak artefacts were still observed in about 20 % of patients
(Fig. 4). Hence the occurrence of streak artefacts might have
reduced the sensitivity of MRI in our study.
The second limitation, whichmight have affected ourMRI-
CT comparison, is that the image quality of the MRI images
was partially impaired by motion artefacts related to pulsation
of the heart and great vessels (Fig. 5). We did not attempt to
reduce these artefacts by using cardiac gating since this would
Fig. 3 Example of underestimation by chest MRI relative to chest CT.
On the left the CT image during inspiration and on the right the
correspondent PROPELLER MRI image. Note the peripheral
bronchiectasis depicted by CT in the right upper lobe tends to disappear
in the correspondent MRI image (white oval). Similarly the small areas of
tree in bud in the left lower lobe are blurred and therefore less visible in
the correspondent MRI image (white dotted oval)
Fig. 4 Streak artefacts of
propeller sequence. On the left the
CT image during inspiration and
on the right the corresponding
MRI image acquired using the
PROPELLER sequence. Note
that streaks artefacts are visible
not only inside the parenchyma
(arrowheads), but also outside
(white arrows)
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have added 5-10 min scan time to an already lengthy MRI
protocol of 35 min (average 20-45 min). Purposely, the PRO-
PELLER sequence was applied with the NAVIGATOR tech-
nique, which reduced problems related to patient cooperation,
especially in younger patients, since the acquisition was auto-
matically triggered at the end of the expiration independently
by the respiratory pattern. A disadvantage of the NAVIGA-
TOR technique was that in children with irregular breathing it
prolonged the acquisition time.
The third limitation of our study was that images were
acquired using different breathing conditions for the CT and
MRI protocols. As discussed, MRI images were acquired near
the functional residual volume level (FRC) using free-
breathing acquisition, while for CT bronchiectasis was
assessed after a deep inspiration at a lung volume close to total
lung capacity while trapped air was assessed at a lung volume
close to residual volume during a breath hold manoeuvre at
end expiration. However, it has been shown that CTs acquired
near the FRC overestimate trapped air relative to scans ac-
quired near residual volume [28]. Therefore, ourMRI protocol
should have shown larger amounts of trapped air compared to
CT, but this was not the case.
Finally, the reduced sensitivity of chest MRI relative to CT
might be related to the use of our CF-MRI semi-quantitative
scoring system. We decided to use a similar scoring strategy
for MRI as for CT to allow a fair comparison between sub-
scores. The CF-MRI scoring system was used by our group
with success in previous studies [13, 14]. As shown by the
good intra- and inter-observer variability both the CF-CT and
CF-MRI scoring systems can be trained reliably. It is possible
that the development of more sophisticated scoring methods
for MRI might improve the sensitivity of MRI.
In conclusion, this comparison showed that motion-
corrected MR image acquisition with PROPELLER does not
show good sensitivity for assessing CF lung disease, and it is
still not able to assess the severity of CF lung disease with the
same precision as CT. However, the good or very good inter-
and intra-observer agreement and the high specificity suggest
that MRI can be applied in the follow-up of CF lung disease.
MRI may be used for short-term follow-up of major lung
abnormalities, such as evaluating the efficacy of intravenous
treatment for a pulmonary exacerbation, and avoiding ionising
radiation, which is an inherent limitation of CT. Likely in
future, further protocol optimisation and alternative, more sen-
sitive image analysis techniques will allow chest MRI to
playing a more important role in the follow-up of CF lung
disease.
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